Starton Therapeutics scraps SPAC deal that would have taken it public, brought in $50M
Starton Therapeutics, which had planned to go public this year in a SPAC merger, said Friday that the $50 million deal announced in April has been terminated.
New Jersey-based Starton was supposed to combine with Healthwell Acquisition Corp. I in a SPAC deal that would have given the biotech about $50 million, put it on the Nasdaq, and set up the combined company to have an equity value of $374 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.